MarketLens
Sign Up

Merck's Soaring P/E Masks Patent Cliffs and Pipeline Setbacks, Triggering Institutional Exit

4 months ago
SHARE THIS ON:

Merck's Soaring P/E Masks Patent Cliffs and Pipeline Setbacks, Triggering Institutional Exit

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

Merck's 2027 growth outlook is challenged by generic pressures, vaccine weakness and a Keytruda slowdown, while its expanding pipeline offers promising long-term potential.
Stock News•2 months ago

Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

Merck's Keytruda faces a 2028 biosimilar threat, as Cipla's copy could erode the $8.4 billion franchise. The warning highlights potential revenue pressure for the drugmaker, priced at $151.07.
Stock News•3 months ago

Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep

Merck extended Keytruda's lifecycle via subcutaneous Qlex and exclusivity through 2039, plus acquisitions of Terns and Cidara. The stock rallied 17% since last quarter, with a 2030–32 P/E of ~13.5, re...

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Cisco Stock Fell 15.5% Despite Its Strongest Growth in 15 Years. Is the Dividend Safe?

Stock News•2 hours ago

Prediction: This Will Be Nvidia's Stock Price in 2027 After Its Phenomenal Q3 Results

Stock News•2 hours ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important December 1 Deadline in Securities Class Action - GOOGL, GOOG

Stock News•3 hours ago

The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026

Stock News•3 hours ago

The S&P 500 Is Having the Longest Losing Streak Since February 2020